A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency

Authors:

Abstract
For anthracycline-based chemotherapy to be immunogenic, dying cancer cells must release annexin A1 (ANXA1) that subsequently interacts with the pattern recognition receptor, formyl peptide receptor 1 (FPR1), on the surface of dendritic cells (DC). Approximately 30% of individuals bear loss-of-function alleles of FPR1, calling for strategies to ameliorate their anticancer immune response. Here, we show that immunotherapy with a ligand of Toll-like receptor-3, polyinosinic:polycytidylic acid (pIC), restores the deficient response to chemotherapy of tumors lacking ANXA1 developing in immunocompetent mice or those of normal cancers growing in FPR1-deficient mice. This effect was accompanied by improved DC- and T-lymphocyte–mediated anticancer immunity. Of note, carcinogen-induced breast cancers precociously developed in FPR1-deficient mice as compared with wild-type controls. A similar tendency for earlier cancer development was found in patients carrying the loss-of-function allele of FPR1. These findings have potential implications for the clinical management of FPR1-deficient patients. Significance: The loss-of-function variant rs867228 in FPR1, harbored by approximately 30% of the world population, is associated with the precocious manifestation of breast, colorectal, esophageal, and head and neck carcinomas. pIC restores deficient chemotherapeutic responses in mice lacking Fpr1, suggesting a personalized strategy for compensating for the FPR1 defect. This article is highlighted in the In This Issue feature, p. 211
Funding Information
  • Novo Nordisk Fonden (NNF15OC0016584)
  • Research and Technology Innovation Fund (KTIA_NAP_13- 2014-0021)
  • Research and Technology Innovation Fund (NAP2-2017-1.2.1-NKP-0002)
  • Breast Cancer Research Foundation (BCRF-18-159)
  • Det Frie Forskningsråd (19#7016-00345B)
  • DOD | United States Army | MEDCOM | Congressionally Directed Medical Research Programs (W81XWH-18-2-0056)
  • Ligue Contre le Cancer
  • Ruban Rose
  • Canceropôle PACA
  • Institut Gustave-Roussy (Odyssea)
  • Institut National Du Cancer
  • Institut National de la Santé et de la Recherche Médicale
  • Institut Universitaire de France
  • Agence Nationale de la Recherche
  • European Commission
  • Université Paris Descartes
  • HTE heterogeneity of tumoral ecosystem
  • Ministère de l'Education Nationale, de l'Enseignement Supérieur et de la Recherche

This publication has 38 references indexed in Scilit: